Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2012-02-06
Original SEC Filing: Click here

---

Webplus: SVA/20120206/6-K/2_EX-99.1/000.htm SEC Original: v301323_ex99-1.htm
Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement Press Release: Sinovac Biotech Co., Ltd. – Tue, Jan 24, 2012 4:05 PM EST BEIJING, Jan. 24, 2012 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA – News), a leading provider of vaccines in China, today announced that it received a letter dated January 18, 2012 from The Nasdaq Stock Market. Based

---

---

Webplus: SVA/20120206/6-K/3_EX-99.2/000.htm SEC Original: v301323_ex99-2.htm
Sinovac Commences the Phase III Clinical Trial for its EV71 Vaccine Against Hand, Foot and Mouth Disease Press Release: Sinovac Biotech Ltd. – Tue, Jan 10, 2012 8:00 AM EST BEIJING , Jan. 10, 2012 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA – News), a leading provider of biopharmaceutical products in China , announced today that the phase III clinical

---

---

Webplus: SVA/20120206/6-K/1/000.htm SEC Original: v301323_6k.htm
SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China Form 20-F x Form 40-F ¨ SINOVAC BIOTECH LTD. 6-K 1 v301323_6k.htm FORM 6-K

---

Company Information:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2012-02-06CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
39 SHANGDI XI ROAD
BEIJING 100085